key: cord-0288246-xb936h2d authors: Rouhani, S. J.; Trujillo, J. A.; Pyzer, A. R.; Yu, J.; Fessler, J. L.; Cabanov, A.; Higgs, E. F.; Cron, K. R.; Zha, Y.; Lu, Y.; Bloodworth, J. C.; Abasiyanik, M. F.; Okrah, S.; Flood, B. A.; Hatogai, K.; Leung, M. Y.; Pezeshk, A.; Kozloff, L.; Reschke, R.; Strohbehn, G. W.; Chervin, C. S.; Kumar, M.; Schrantz, S.; Madariaga, M. L.; Beavis, K. G.; Yeo, K.-T. J.; Sweis, R.; Segal, J.; Tay, S.; Izumchenko, E.; Mueller, J.; Chen, L. S.; Gajewski, T. F. title: Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction date: 2021-12-11 journal: nan DOI: 10.1101/2021.12.09.21266492 sha: fe2ab59c3ebf108451ee04f49cd35c605257e290 doc_id: 288246 cord_uid: xb936h2d The mechanisms explaining progression to severe COVID-19 remain poorly understood. It has been proposed that immune system dysregulation or over-stimulation may be implicated, but it is not clear how such processes would lead to respiratory failure. We performed comprehensive multiparameter immune monitoring in a tightly controlled cohort of 128 COVID-19 patients, and used the ratio of oxygen saturation to fraction of inspired oxygen (SpO2 to FiO2) as a physiologic measure of disease severity. Machine learning algorithms integrating 139 parameters identified IL-6 and CCL2 as two factors predictive of severe disease, consistent with the therapeutic benefit observed with anti-IL6-R antibody treatment. However, transcripts encoding these cytokines were not detected among circulating immune cells. Rather, in situ analysis of lung specimens using RNAscope and immunofluorescent staining revealed that elevated IL-6 and CCL2 were dominantly produced by infected lung type II pneumocytes. Severe disease was not associated with higher viral load, deficient antibody responses, or dysfunctional T cell responses. These results refine our understanding of severe COVID-19 pathophysiology, indicating that aberrant cytokine production by infected lung epithelial cells is a major driver of immunopathology. We propose that these factors cause local immune regulation towards the benefit of the virus. The clinical manifestations of COVID-19 range in severity from asymptomatic infection to critical 43 illness and death, yet the mechanisms by which SARS-CoV-2 cause morbidity and mortality have yet to be 44 fully elucidated. It has been proposed that an excessive immune response may cause immunopathology in 45 affected target organs, particularly the lower respiratory tract. Several large studies of hospitalized patients 46 demonstrated that disease severity and mortality are correlated with elevated levels of inflammatory 47 cytokines, suggesting a potentially dysregulated immune response to infection 1-4 . Consistent with this 48 notion, the steroid dexamethasone improved outcomes in severe and critically ill patients 5,6 . IL-6 specifically 49 has been proposed as a functionally important cytokine, 7 and the anti-IL-6R antibody (Ab) tocilizumab 50 provided a survival benefit in critically ill COVID-19 patients 8, 9 . CD38 and HLA-DR are markers of activated T cells during viral infections 25 , and this population 122 was increased among both CD4 + and CD8 + T cells in COVID-19 patients of all disease severities (Fig 2b) . It was particularly striking in CD8 + T cells, where 42% (21 / 50) of patients had > 5% of all CD8 + T cells 124 expressing these activation markers between days 10-30. Thus, despite a relative overall lymphopenia, 125 there was an abundance of activated T cells in severe patients. Self-clustering analysis using UMAP and 126 FlowSOM algorithms 26 showed COVID-19 patients had increased percentages of activated CD8 + (cluster 127 4) and CD4 + (cluster 11) cells expressing high levels of CD38, HLA-DR, and CD95 ( Supplementary Fig 4c- 128 e). CD8 + CM cells and multiple subsets of CD4 + T cells upregulated CD28 ( Supplementary Fig 4a,4b) . There were no significant differences in the percentages of CD4 + or CD8 + T cells expressing PD-1, although 130 modest upregulation of PD-1 was seen on CD4 + EM and CD8 + EM and TEMRA cells (Fig 2c, 131 Supplementary Fig 4a,b) . There was an increased percentage of CD8 + T cells expressing TIM-3 (Fig 2c) . The proportion of regulatory T cells (Tregs) also increased in COVID-19 patients (Fig 2a) , suggesting a 133 counter-regulatory mechanism in response to increasing levels of T cell activation. Several studies have shown that inhibitory receptors including PD-1 are upregulated on SARS- CoV-2 specific T cells, and have suggested that PD-1 high cells in COVID-19 infection are exhausted 17, [27] [28] [29] 136 or have decreased polyfunctionality 28, 30 . However, PD-1 can also be upregulated in acutely activated T 137 cells 3,31 . To determine whether there were differences in IFN-γ production by SARS-CoV-2-specific T cells, 138 we used an ELISPOT to measure IFN-γ production after stimulation with overlapping HLA class I & II 15-139 mer peptides from the S, M, and N proteins of SARS-CoV-2. IFN-γ production was seen as early as day 8 140 after symptom onset, and the degree of IFN-γ production was similar between patients with different 141 disease severities (Supplementary Fig 4f) . To determine if PD-1 on these cells represents a marker of activation or exhaustion, we used 143 intracellular cytokine staining to measure polyfunctionality after S/M/N peptide stimulation. Compared to 144 mild patients, severe patients had higher percentages of polyfunctional CD4 + T cells producing IFN-γ, TNF-145 α, and/or IL-2 in response to S/M/N peptide stimulation (Fig 2d-f ). Furthermore, cytokine production was 146 concentrated in the PD-1 + CD4 + T cells, indicating that PD-1 represents an activation marker rather than a 147 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 marker of dysfunction in this context. There was a similar trend with PD-1 + CD8 + T cells in severe patients, 148 but this was not significant due to increased patient-to-patient variability in the CD8 + T cell response 149 ( Supplementary Fig 4g) . Cytokine-producing T cells were enriched amongst the CD38 + HLA-DR + population 150 (Fig 2d,2f) , consistent with this population containing virus-activated T cells. We conclude that the adaptive 151 immune response is robust in severe COVID-19 patients and that lack of virus-specific immunity is not 152 contributory to the progression to disease severity. Patients with SARS-CoV-2 also had a serum cytokine and chemokine profile consistent with 154 increased T cell activation. Levels of CCL19 and CCL20, which recruit T cells to lymph nodes for activation, 155 increased with disease severity (Fig 2g) . Severe patients had higher levels of sCD25/IL-2Ra, which is 156 cleaved and released upon T cell activation. CCL5 and CXCL10 recruit T cells to sites of inflammation, 157 and were elevated in the serum of COVID-19 patients. CXCL10 also increased with disease severity. Levels of CCL19, CCL20, and CD25/IL-2Ra remained elevated over time in severe patients, while CCL5 159 and CXCL10 levels declined over time in both mild and severe patients (Fig 2h) . Patients with severe Fig 5a) . However, the level of CD86 increased in plasmacytoid DCs, 169 indicating a more activated status. CD1c + DCs also had higher levels of Tim-3 at late time points after 170 SARS-CoV-2 infection. The proportions of neutrophils, non-classical monocytes, and intermediate 171 monocytes were increased in patients with COVID-19 compared to healthy controls (Fig 3a) . While the 172 percentage of classical monocytes was unchanged, the mean fluorescence intensity (MFI) of CD86 and 173 HLA-DR was decreased in infected patients (Fig 3a) , suggesting the emergence of less-mature monocytes 174 from the bone marrow. This is further supported by increased levels of the myeloid growth factor GM-CSF 175 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 in the serum of patients with SARS-CoV-2 infection (Fig 3b) , and a negative correlation between GM-CSF 176 and HLA-DR levels on intermediate monocytes (R 2 = 0.15, p = 0.004) (Supplementary Fig 5c) . These 177 parameters are consistent with tissue repair-type macrophages being favored during SARS-CoV-2 178 infection. Patients with SARS-CoV-2 had increased levels of cytokines responsible for recruiting neutrophils, 180 monocytes and macrophages to sites of inflammation, including the neutrophil chemoattractants IL-8, 181 CXCL1, CXCL2, and the monocyte chemoattractants CCL2, CCL4, and CX3CL1 (Fig 3b) . CCL2, and 182 CX3CL1 also increased with disease severity. Distinct groups of cytokines clustered together in correlation 183 plots at late time points (Fig 3c) , particularly in severe patients. CCL2 levels remained high over time in 184 severe patients, and higher levels of CCL2 also correlated with a longer duration of moderate or severe 185 illness (R 2 = 0.17, p = 0.00737) (Fig 3d-e) . IL-6 has been identified as a pathologic mediator of cytokine release syndrome after CAR-T cell 187 treatment, and it has been hypothesized that a similar phenomenon may be driving severe pathology in 188 some COVID-19 patients 7 . IL-6 signals through the IL-6R and gp130 complex. Gp130 is ubiquitously 189 expressed, while IL-6R expression is normally limited to immune cells and hepatocytes. IL-6 can also form 190 a complex with soluble IL-6R (sIL-6R!) and signal in trans through gp130 in cells that do not express the 191 IL-6R. We found that IL-6 levels increased with disease severity, while sIL-6R! and gp130 levels were 192 similar between severity groups (Fig 3b) . While there was a correlation between CRP and IL-6 levels, there 193 were many patients who had a high CRP but only a modest increase in IL-6 ( Supplementary Fig 5d) . Levels 194 of IL-6 remained high at late timepoints in severe patients when compared to mild (Fig 3d) , and levels of 195 soluble gp130 were lower in severe patients at late timepoints ( Supplementary Fig 5e) . sIL-6R! levels 196 remained high over time in both mild and severe patients. Interestingly, the duration of moderate or severe 197 disease positively correlated with IL-6 levels and negatively correlated with soluble levels of gp130, which 198 is an endogenous inhibitor of IL-6 trans-signaling 34-37 (Fig 3e, Supplementary Fig 5f) . In order to better understand the pathophysiology that differentiates severe patients from mild or preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 determine the relative impact of each feature. At early time points (D1-9), severe patients showed evidence 204 for an active innate immune response (elevated G-CSF, IL-8, and the percentage of neutrophils) as well as 205 an activated T cell response (elevated CXCL10, with the anti-IL-6R antibody tocilizumab 9 . Based on prior work studying cytokine-release syndrome in CAR- T cell therapy 38,39 and IL-6 production in infectious models 40-42 , it has been assumed that IL-6 in COVID-19 218 patients is being produced by macrophages 43 . However, in our cohort examining representative patients 219 having "high" versus "low" serum IL-6 levels at the protein level ( Supplementary Fig 6a) , no difference in 220 mRNA for either IL-6 or CCL2 was observed among peripheral level blood mononuclear cells 221 ( Supplementary Fig 6c-d) . This result is consistent with the flow cytometric analysis of circulating 222 monocytes, which indicated an immature and possibly tissue repair phenotype rather than an inflammatory 223 one (Fig 3a) . Together, these results suggested that the source of these cytokines might not be immune 224 cells, but rather raised the possibility that virus-infected cells in the lung might be the major source. We 225 therefore examined expression of IL-6 and CCL2 mRNA in lung tissue from a cohort of 10 fatal COVID-19 226 cases listed in Supplementary Table 3 . We performed a multispectral immunofluorescence assay 227 combining RNA in situ hybridization (RNA-ISH) for SARS-CoV-2 RNA and IL-6 or CCL2 mRNA, along with 228 protein immunofluorescence (IF) staining to identify the cells of origin. Thyroid transcription factor 1 (TTF1) 229 was used to identify type 2 pneumocytes, and CD45 was utilized to identify leukocytes (Fig 4a, 230 Supplementary Fig 7a) . SARS-CoV-2 RNA was detected in all of the autopsy lung specimens. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Unexpectedly, the vast majority of IL-6 transcripts were detected in cells that did not co-stain for the 232 macrophage markers CD68 or the M2 macrophage marker CD163 ( Supplementary Fig 6e-f ). Interestingly, 233 large numbers of TTF1 + type 2 pneumocytes expressed IL-6 mRNA, with a high percentage of these cells 234 also positive for SARS-CoV-2 RNA (Fig 4a-c) . Quantitative analysis showed TTF1 + type 2 pneumocytes 235 were the predominant IL-6-expressing cell type, greatly outnumbering CD45 + immune cells (Fig 4b,c) . Among the IL-6 positive populations, type 2 pneumocytes relative to CD45 + cells showed greater IL-6 237 expression on a per cell basis, as indicated by a greater number of TTF1 + cells with higher mean staining 238 intensity for IL-6 (Fig 4d) . Similarly, CCL2 expression was particularly abundant on TTF2 + type 2 239 pneumocytes ( Supplementary Fig 7a-d) . Together these data show that virus-infected lung epithelial cells 240 are the major source of IL-6 and CCL2 in SARS-CoV-2 infected lungs. Here we show that IL-6 and CCL2 are major factors that discriminate severe infection from mild or 244 moderate disease. IL-6 is known to be produced by innate immune cells such as macrophages or dendritic 245 cells, and by non-immune cells such as epithelial cells or fibroblasts. In allergic asthma 44,45 , SARS-CoV-246 1 40 , influenza 41 , and pneumovirus infection models 42 , IL-6 has been shown to be produced by macrophages 247 and other myeloid cells, whereas IL-6 can be produced by cultured nasal epithelial cells infected with 248 RSV 46,47 . In mouse models of CAR-T cell cytokine release syndrome, macrophages and monocytes are 249 the predominant source of IL-6 38,39 , while vascular endothelial cells have also been shown to produce IL-6 250 in CRS autopsy specimens 48 . Our results from human autopsy specimens unexpectedly show that the 251 predominant source of IL-6 and CCL2 in vivo during SARS-CoV-2 infection is from infected epithelial cells. Our data are consistent with scRNA-seq studies of PBMCs from COVID-19 patients that showed a 253 discrepancy between serum cytokine measurements and the cytokine transcripts of CCL2 and IL-6 among 254 PBMCs 49-53 . Large numbers of epithelial pneumocytes co-stained with IL-6 or CCL2 and SARS-CoV-2 RNA 255 probes, implicating direct cytokine induction by the virus. When considering potential mechanisms of 256 cytokine production, it has been demonstrated that SARS-CoV-2 induces Nuclear Factor kappa B (NF-kB) 257 upregulation and IL-6 production in cultured lung alveolar and epithelial cells 54,55 . CCL2 and other 258 inflammatory mediators are also induced via the NF-kB pathway 56 . All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 In mouse models of coronavirus infections, sustained CCL2 expression enhanced the lethality of 260 disease, and promoted immunopathology with a destructive monocyte/macrophage response and 261 ineffective virus clearance 57 . The effect of excess CCL2 in human SARS-CoV-2 has not yet been 262 elucidated. CCL2 may recruit wound-healing M2 macrophages, which can facilitate lung tissue repair by 263 stimulating type 2 pneumocyte expansion 58 , thereby triggering a process capable of enhancing virus 264 propagation 59 . The anti-IL-6R antibody tocilizumab improves survival in critically ill patients 9 , implying that 265 excessive IL-6 is detrimental to the host. Elevated levels of IL-6 in cancer models have been mechanistically 266 linked to decreased DC survival and activation, and consequently impaired CD8 + T cell priming 60 . As such, Robust adaptive immune responses were seen in patients with mild and moderate disease and 280 were even higher in patients with severe disease, arguing that the lack of a protective immune response 281 did not cause severe disease. CD38 + HLA-DR + CD4 + and CD8 + T cells were polyfunctional, and patients 282 with a higher disease severity had more cytokine producing CD4 + T cells. These cytokines were being 283 produced by PD-1 + cells, indicating that PD-1 in this context is a marker of activation, not exhaustion. This 284 is consistent with other recent work showing that tetramer + PD-1 + , SARS-CoV-2-specific CD8 + T cells 285 produce cytokines 62 . In patients with severe disease, markers of T cell activation such as sCD25/IL-2R 286 remain high at late time points, suggesting an ongoing immune response against the virus. In some severe 287 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 patients who ultimately die from SARS-CoV-2, persistent viral RNA has been demonstrated in longitudinal 288 saliva samples from the Iwasaki group 63 , as well as in our autopsy lung samples. Increased antigen load 289 and duration of antigenic exposure leads to increased T and B cell expansion and differentiation in other 290 experimental models 64 . While we cannot rule out that the increased adaptive immune response causes 291 immunopathology, the increase in regulatory modulators such as IL-10 and Tregs suggests that the immune 292 system is appropriately executing negative feedback pathways. Our data suggests that the immune 293 response to SARS-CoV-2 is a functional and proportional response to infection, and infected pneumocytes 294 are the major source of IL-6 and CCL2, thus revising the paradigm of how we understand the pathogenesis 295 of severe SARS-CoV-2 infection. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Cardiogenic shock in a patient with end stage heart failure; out of hospital cardiac arrest Delivered of a pregnancy during admission for SARS-CoV-2 298 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 307 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Correspondence and requests for material or data should be directed to TFG. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Immunol. 98, 1080-1087 (1996) . All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For serum, fresh blood was collected into a preservative-free vacutainer tube and allowed to clot 521 for at least 30 minutes at room temperature. Leftover plasma samples collected in heparinized tubes were 522 also obtained from the clinical chemistry lab. Tubes were centrifuged for 20 minutes at 1300 x g at room 523 temperature, and the yellow serum/plasma layers were collected and stored at -80 degC until analysis. For PBMCs, fresh blood was collected into heparinized vacutainer tubes and separated using 525 LeucoSep (Greiner Bio-One) tubes. Cells were washed twice with PBS, counted and resuspended in 526 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The reaction was stopped after 15 minutes with 2M sulfuric acid. The optical density (OD) was read at 450 568 nm using a Synergy H4 plate reader (BioTek). The OD values for each sample were background subtracted. A positive control standard was prepared from plasma samples pooled from 6 COVID-19-infected patients, preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.09.21266492 doi: medRxiv preprint and 0.5 ug anti-CD28/CD49d was added into the media with the PBMCs. 0.1 ug/mL phorbol myristate 611 acetate (PMA) and 1 ug/mL ionomycin were to the appropriate wells with PBMCs. The unstimulated 612 condition was also treated with 0.5 ug anti-CD28/CD49d. All conditions were incubated for 9 hours in the 613 presence of Golgiplug/Golgistop at manufacturer's recommended concentration (BD Biosciences). After 614 stimulation, 2 mM EDTA was added to the anti-CD3/CD28/CD49d wells and incubated for 15 minutes. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101/2021.12.09.21266492 doi: medRxiv preprint control. PBMCs in separate wells were stimulated with peptides from either the spike protein ("S"), 640 membrane glycoprotein ("M") or nucleocapsid phosphoprotein ("N") (all from Miltenyi Biotec) at 1 ug/mL. SIYRYYGL (SIY peptide) was used as a negative (irrelevant) peptide control in each experiment with ≤1 642 spot seen in each irrelevant well. The total number of PBMCs recovered after thawing was divided into 643 12 wells, with PMA + Ionomycin controls plated at 10% of the cell density as other wells. Average cell 644 number per experimental well was 218,000, with a range of 50,000 -750,000 cells for experimental wells. Cells were incubated at 37°C with 5% CO2 with activating stimuli for 18 hours in CTL-Test Medium 646 (ImmunoSpot) with 1% L-glutamine (Gibco) prior to developing plates per manufacturer's recommended 647 procedure. Plates were scanned using ImmunoSpot analyzer and spots were counted using ImmunoSpot with RNA eluted in 60 μL of AVE buffer. Digital droplet PCR (ddPCR) was performed as previously 656 described 67 . Briefly, a 20 uL reaction was performed with 2 uL N1/N2/RNaseP probe primer sets (IDT 657 #10006770), 5 uL one-step ddPCR supermix, 2 uL reverse transcriptase, 1 uL 300 mM DTT, and 6 uL 658 sample RNA. Amplification was performed under the following conditions: 25°C for 2 min, 50°C for 60 min, 659 95°C for 10 min, 45 cycles of [95°C for 30 seconds, 55°C for 1 min, then 98°C for 10 min], followed by 660 infinite hold at 4°C. Ramping speed was 2.5°C/s. Fluorescence was read using a QX200 droplet reader 661 (Bio-Rad) and analyzed with Quantasoft software. Threshold of positivity defined in the manufacturer's FDA 662 emergency use authorization approval was used (>0.1 copy number / μL for either N1 or N2 and more than 663 2 positive droplets per reaction). Viral load is reported as the average of the N1 and N2 copy number / μL. Multiplexed staining combining RNA-ISH and immunofluorescence staining for protein 666 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 To determine which features were predictive of disease severity, the Random Forest R package 722 randomForest 69 was used and area under the ROC curve (AUC) calculated. A 3-fold cross-validation was 723 used and the mean AUC on the test data set was presented. Models were trained for early phase (D0-D9), 724 late phase (D10-D30), and all timepoints (D0-D30) separately. Correlation plots and the machine learning 725 algorithm were processed using R studio (R 3.6.1). Flow cytometry data were processed using FlowJo V10.7.1. Graphs were created and statistics 727 performed using either GraphPad Prism v9.0.0 or R 4.0.3 (R Core Team, 2020 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this this version posted December 11, 2021. ; https://doi.org/10.1101 /2021 doi: medRxiv preprint FiO2 is depicted on the right. Each dot represents an individual S/F ratio calculated based on the simultaneous oxygen saturation and FiO2 recorded for hospitalized patients; all available timepoints per day per patient are shown. Oxygen delivery categories are labelled on the X axis. Colored shaded areas indicate S/F ratios which correspond to mild (green), moderate (orange) and severe (red) disease severity categories. (b) Serum SARS-CoV-2 total Ig antibody levels (RBD and Spike) in (n=68) PCR+ patients over time expressed as days post symptom onset (DPSO). Samples from individual patients are connected by lines, and colored by disease severity (mild in green, moderate in orange, severe in red). The dashed line indicates the max titer of a pool of negative controls, used as the threshold for positivity. Samples post receipt of convalescent plasma transfusion were excluded from this and all antibody analyses. (c) Maximum serum SARS-CoV-2 IgG (red) and IgM (turquoise) antibody levels (RBD and Spike) in PCR+ patients during acute phase of infection (day 10-19) (n=31), recovery (day 20-59) (n=9), and late recovery (day 60-120) (n=5), where day is DPSO. Data from the pre-humoral phase (